Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Titel:
Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Auteur:
Reilly, Timothy P. Graziano, Michael J. Janovitz, Evan B. Dorr, Thomas E. Fairchild, Craig Lee, Francis Chen, Jian Wong, Tai Whaley, Jean M. Tirmenstein, Mark